Supplementation and therapeutic use of vitamin D in patients with multiple sclerosis: Consensus of the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology;Suplementação e uso terapêutico de vitamina D nos pacientes com esclerose múltipla: Consenso do Departamento Científico de Neuroimunologia da Academia Brasileira de Neurologia

Arquivos de Neuro-Psiquiatria

Volumn 72, Issue 2, 2014, Pages 152-156

  Brum, Doralina Guimarães ^a   Comini Frota, Elizabeth Regina ^b   Vasconcelos, Claúdia Cristina F ^c   Dias Tosta, Elza ^d  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d HOSPITAL DE BASE DO DISTRITO FEDERAL   (Brazil)

Author keywords

Experimental autoimmune encephalitis; Multiple sclerosis; Vitamin D

Indexed keywords

VITAMIN D;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; BRADYCARDIA; CARDIOMYOPATHY; COMA; CONSTIPATION; DIABETES INSIPIDUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCALCEMIA; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY CALCIFICATION; KIDNEY FAILURE; MASS SPECTROMETRY; META ANALYSIS (TOPIC); MONOTHERAPY; MULTIPLE SCLEROSIS; NAUSEA; NEPHROLITHIASIS; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PARESTHESIA; PHASE 2 CLINICAL TRIAL (TOPIC); POLYDIPSIA; POLYURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; VOMITING;

CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; HUMANS; MULTIPLE SCLEROSIS; VITAMIN D; VITAMINS;

EID: 84894514614     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/0004-282X20130252     Document Type: Article

References (37)

1. Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev 2005;10:94-111.
2. Bikle DD. Vitamin D regulation of immune function. Vitam Horm 2011;86:1-21.
3. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metabl 2011;96:1911-1930.
4. Rosen CJ, Abrams SA, Aloia JF, et al. IOM committee members respond to Endocrine Society vitamin D guideline. J Clin Endocrinol Metab 2012;97:1146-1152.
5. Holick MF. Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers. South Med J 2005;98:1024-1027.
6. Kurtzke J. A reassessment of the distribution of multiple sclerosis. Acta Neurol Scand 1975;51:137-157.
7. Hossein-nezhad A, Holick MF. Vitamin D for health: a global perspective. Mayo Clin Proc 2013;88:720-755.
8. Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses 1986;21:193-200.
9. Martinelli V, Dalla Costa G, Colombo B, et al. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler 2013, Epub Ahead of Print
10. Ebers GC, Bulman DE, Sadovnick AD, et al. A populationbased study of multiple sclerosis in twins. N Engl J Med 1986;315:1638-1642.
11. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214-219.
12. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 2004;229:1136-1142.
13. Lucas RM, Ponsonby AL, Dear K, et al. Current and past Epstein-Barr virus infection in risk of initial CNS demyelination. Neurology 2011;77:371-379.
14. Hedström AK, Sundqvist E, Bäärnhielm M, et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain 2011;134:653-664.
15. Ascherio A, Munger K. Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol 2008;28:17-28.
16. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-2838.
17. Maeda SS, Saraiva GL, Kunii IS, et al. Factors affecting vitamin D status in different populations in the city of Sao Paulo, Brazil: the Sao PAulo vitamin D Evaluation Study (SPADES). BMC Endocr Disord 2013;13:14.
18. Libon F, Cavalier E, Nikkels AF. Skin color is relevant to vitamin D synthesis. Dermatology 2013;227:250-254.
19. Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008;14:1220-1224.
20. Arantes HP, Kulak CA, Fernandes CE, et al. Erratum to: correlation between 25-hydroxyvitamin D levels and latitude in Brazilian postmenopausal women: from the Arzoxifene Generations Trial. Osteoporos Int 2013;24:2899-2900.
21. Kimball S, Vieth R, Dosch HM, et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. J Clin Endocrinol Metab 2011;96:2826-2834.
22. Allen AC, Kelly S, Basdeo SA, et al. A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers. Mult Scler 2012;18:1797-1800.
23. Farias AS, Spagnol GS, Bordeaux-Rego P, et al. Vitamin D3 induces IDO(+) tolerogenic DCs and enhances Treg, reducing the severity of EAE. CNS Neurosci Ther 2013;19:269-277.
24. Correale J, Ysrraelit MC, Gaitán MI. Vitamin D-mediated immune regulation in multiple sclerosis. J Neurol Sci 2011;311:23-31.
25. Soilu-Hänninen M, Aivo J, Lindström BM, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:565-571.
26. Kampman MT, Steffensen LH, Mellgren SI, Jørgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Sclerg 2012;18:1144-1151.
27. Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H. Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult Scler Int 2012;2012:452-541.
28. Stein MS, Liu Y, Gray OM, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011;77:1611-1618.
29. James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan SV. The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Mult Scler 2013;19:1571-1579.
30. Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012;72:234-240.
31. Gallo S, Comeau K, Vanstone C, et al. Effect of different dosages of oral vitamin D supplementation on vitamin D status in healthy, breastfed infants: a randomized trial. JAMA 2013;309:1785-1792.
32. Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010;74:1852-1859.
33. Roth HJ, Schmidt-Gayk H, Weber H, Niederau C. Accuracy and clinical implications of seven 25-hydroxyvitamin D methods compared with liquid chromatography-tandem mass spectrometry as a reference. Ann Clin Biochem 2008;45:153-159.
34. Koul PA, Ahmad SH, Ahmad F, Jan RA, Shah SU, Khan UH. Vitamin d toxicity in adults: a case series from an area with endemic hypovitaminosis d. Oman Med J 2011;26:201-204.
35. Zittermann A, Prokop S, Gummert JF, Börgermann J. Safety issues of vitamin D supplementation. Anticancer Agents Med Chem 2013;13:4-10.
36. Ashizawa N, Arakawa S, Koide Y, Toda G, Seto S, Yano K. Hypercalcemia due to vitamin D intoxication with clinical features mimicking acute myocardial infarction. Intern Med 2003;42:340-344.
37. Bell DA, Crooke MJ, Hay N, Glendenning P. Prolonged vitamin D intoxication: presentation, pathogenesis and progress. Intern Med J 2013;43:1148-1150.